teaser
PRNewswire–EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT(R) (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.
The data also show that PROSTASCINT images can be a significant predictor of disease-free survival. The data are available online in the International Journal of Radiation Oncology Biology Physics, the official journal of the American Society for Radiology and Oncology, prior to publication in the December 2010 issue.
PROSTASCINT is a US FDA approved monoclonal antibody-based radiopharmaceutical imaging agent for use in newly-diagnosed patients with biopsy-proven prostate cancer. It is also used in post-prostatectomy patients where there is a high clinical suspicion of hidden metastatic disease.
“These long-term outcomes data demonstrate the significant benefits PROSTASCINT imaging offers as a tool for defining tumour stage prior to treatment and for enabling image-guided radiotherapy in clinically localised prostate cancer,” stated the study’s Principal Investigator, Rodney J. Ellis, M.D., Vice-Chairman for Clinical Research and Director of Genito-Urinary Oncology, Brachytherapy, and Advanced Image Guided Radiotherapy at Case Western Reserve University and University Hospitals of Cleveland.
“This study reports excellent outcomes when PROSTASCINT is utilised to direct increased radiation doses to regions of the prostate with higher tumor burden, and shows its utility as a predictive tool, identifying patients who may require increased vigilance in post-therapy follow-up, and/or those patients who might benefit from more aggressive treatment, such as adjuvant chemotherapy,” he said.
